Eastchester Road Dialysis Center is a medicare approved dialysis facility center in Bronx, New York and it has 12 dialysis stations. It is located in Bronx county at Liberty R.c. Inc., Bronx, NY, 10461. You can reach out to the office of Eastchester Road Dialysis Center at (718) 822-4940. This dialysis clinic is managed and/or owned by Davita. Eastchester Road Dialysis Center has the following ownership type - Profit. It was first certified by medicare in November, 2007. The medicare id for this facility is 332656 and it accepts patients under medicare ESRD program.
Name | Eastchester Road Dialysis Center |
---|---|
Location | Liberty R.c. Inc., Bronx, New York |
No. of Dialysis Stations | 12 |
Medicare ID | 332656 |
Managed By | Davita |
Ownership Type | Profit |
Late Shifts | No |
Liberty R.c. Inc., Bronx, New York, 10461 | |
(718) 822-4940 | |
News Archive
Leaping tall buildings in a single bound may be out of the question, but the genetically engineered "supermice" in Ormond MacDougald's laboratory at the University of Michigan Medical School are definitely stronger than average.
A new study by researchers at Wake Forest Baptist Medical Center has shown that aggressive lowering of blood pressure in people with hypertension reduced the risk of left ventricular hypertrophy (LVH).
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").
A study funded by research charity Fight for Sight aims to understand the role that our own immune cells play in the development of macular scarring.
› Verified 5 days ago
NPI Number | 1013410133 |
Organization Name | University Heights Dialysis |
Doing Business As | Knickerbocker Dialysis Inc |
Address | 2190 Jerome Ave Bronx, New York, 10453 |
Phone Number | (718) 584-5746 |
News Archive
Leaping tall buildings in a single bound may be out of the question, but the genetically engineered "supermice" in Ormond MacDougald's laboratory at the University of Michigan Medical School are definitely stronger than average.
A new study by researchers at Wake Forest Baptist Medical Center has shown that aggressive lowering of blood pressure in people with hypertension reduced the risk of left ventricular hypertrophy (LVH).
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").
A study funded by research charity Fight for Sight aims to understand the role that our own immune cells play in the development of macular scarring.
› Verified 5 days ago
NPI Number | 1043377922 |
Organization Name | Eastchester Road Dialysis Center |
Doing Business As | Liberty Rc Inc |
Address | 1515 Jarret Pl Bronx, New York, 10461 |
Phone Number | (718) 822-4940 |
News Archive
Leaping tall buildings in a single bound may be out of the question, but the genetically engineered "supermice" in Ormond MacDougald's laboratory at the University of Michigan Medical School are definitely stronger than average.
A new study by researchers at Wake Forest Baptist Medical Center has shown that aggressive lowering of blood pressure in people with hypertension reduced the risk of left ventricular hypertrophy (LVH).
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").
A study funded by research charity Fight for Sight aims to understand the role that our own immune cells play in the development of macular scarring.
› Verified 5 days ago
NPI Number | 1063911659 |
Organization Name | Mount Eden Dialysis |
Doing Business As | Knickerbocker Dialysis Inc |
Address | 1490 Macombs Rd Bronx, New York, 10452 |
Phone Number | (718) 588-2347 |
News Archive
Leaping tall buildings in a single bound may be out of the question, but the genetically engineered "supermice" in Ormond MacDougald's laboratory at the University of Michigan Medical School are definitely stronger than average.
A new study by researchers at Wake Forest Baptist Medical Center has shown that aggressive lowering of blood pressure in people with hypertension reduced the risk of left ventricular hypertrophy (LVH).
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").
A study funded by research charity Fight for Sight aims to understand the role that our own immune cells play in the development of macular scarring.
› Verified 5 days ago
NPI Number | 1063932945 |
Organization Name | Laconia Dialysis |
Doing Business As | Knickerbocker Dialysis Inc |
Address | 3440 Boston Rd Bronx, New York, 10469 |
Phone Number | (718) 798-0538 |
News Archive
Leaping tall buildings in a single bound may be out of the question, but the genetically engineered "supermice" in Ormond MacDougald's laboratory at the University of Michigan Medical School are definitely stronger than average.
A new study by researchers at Wake Forest Baptist Medical Center has shown that aggressive lowering of blood pressure in people with hypertension reduced the risk of left ventricular hypertrophy (LVH).
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").
A study funded by research charity Fight for Sight aims to understand the role that our own immune cells play in the development of macular scarring.
› Verified 5 days ago
NPI Number | 1275032856 |
Organization Name | Allerton Dialysis |
Doing Business As | Knickerbocker Dialysis Inc |
Address | 2554 White Plains Rd Bronx, New York, 10467 |
Phone Number | (718) 231-1285 |
News Archive
Leaping tall buildings in a single bound may be out of the question, but the genetically engineered "supermice" in Ormond MacDougald's laboratory at the University of Michigan Medical School are definitely stronger than average.
A new study by researchers at Wake Forest Baptist Medical Center has shown that aggressive lowering of blood pressure in people with hypertension reduced the risk of left ventricular hypertrophy (LVH).
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").
A study funded by research charity Fight for Sight aims to understand the role that our own immune cells play in the development of macular scarring.
› Verified 5 days ago
NPI Number | 1730676743 |
Organization Name | West Farms Dialysis |
Doing Business As | Knickerbocker Dialysis Inc |
Address | 1820 E Tremont Ave Bronx, New York, 10460 |
Phone Number | (615) 320-4414 |
News Archive
Leaping tall buildings in a single bound may be out of the question, but the genetically engineered "supermice" in Ormond MacDougald's laboratory at the University of Michigan Medical School are definitely stronger than average.
A new study by researchers at Wake Forest Baptist Medical Center has shown that aggressive lowering of blood pressure in people with hypertension reduced the risk of left ventricular hypertrophy (LVH).
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").
A study funded by research charity Fight for Sight aims to understand the role that our own immune cells play in the development of macular scarring.
› Verified 5 days ago
NPI Number | 1962957993 |
Organization Name | Hutchinson River Dialysis |
Doing Business As | Knickerbocker Dialysis Inc |
Address | 2331 Eastchester Rd Bronx, New York, 10469 |
Phone Number | (718) 547-0612 |
News Archive
Leaping tall buildings in a single bound may be out of the question, but the genetically engineered "supermice" in Ormond MacDougald's laboratory at the University of Michigan Medical School are definitely stronger than average.
A new study by researchers at Wake Forest Baptist Medical Center has shown that aggressive lowering of blood pressure in people with hypertension reduced the risk of left ventricular hypertrophy (LVH).
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").
A study funded by research charity Fight for Sight aims to understand the role that our own immune cells play in the development of macular scarring.
› Verified 5 days ago
Experience Measure | Provider | National Avg. |
---|---|---|
Patients who reported that nephrologists always communicated and cared for them. | 77% | 67% |
Patients who reported that nephrologists usually communicated and cared for them. | 17% | 15% |
Patients who reported that nephrologists sometimes or never communicated and cared for them. | 6% | 18% |
Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 67% | 60% |
Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 21% | 26% |
Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 12% | 14% |
News Archive
Leaping tall buildings in a single bound may be out of the question, but the genetically engineered "supermice" in Ormond MacDougald's laboratory at the University of Michigan Medical School are definitely stronger than average.
A new study by researchers at Wake Forest Baptist Medical Center has shown that aggressive lowering of blood pressure in people with hypertension reduced the risk of left ventricular hypertrophy (LVH).
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").
A study funded by research charity Fight for Sight aims to understand the role that our own immune cells play in the development of macular scarring.
› Verified 5 days ago
Experience Measure | Provider | National Avg. |
---|---|---|
Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 69% | 62% |
Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 18% | 20% |
Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 13% | 18% |
Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 58% | 62% |
Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 32% | 26% |
Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 10% | 12% |
News Archive
Leaping tall buildings in a single bound may be out of the question, but the genetically engineered "supermice" in Ormond MacDougald's laboratory at the University of Michigan Medical School are definitely stronger than average.
A new study by researchers at Wake Forest Baptist Medical Center has shown that aggressive lowering of blood pressure in people with hypertension reduced the risk of left ventricular hypertrophy (LVH).
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").
A study funded by research charity Fight for Sight aims to understand the role that our own immune cells play in the development of macular scarring.
› Verified 5 days ago
Experience Measure | Provider | National Avg. |
---|---|---|
Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 87% | 80% |
Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 13% | 20% |
Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 52% | 68% |
Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 39% | 20% |
Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 9% | 12% |
News Archive
Leaping tall buildings in a single bound may be out of the question, but the genetically engineered "supermice" in Ormond MacDougald's laboratory at the University of Michigan Medical School are definitely stronger than average.
A new study by researchers at Wake Forest Baptist Medical Center has shown that aggressive lowering of blood pressure in people with hypertension reduced the risk of left ventricular hypertrophy (LVH).
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").
A study funded by research charity Fight for Sight aims to understand the role that our own immune cells play in the development of macular scarring.
› Verified 5 days ago
Dialysis patients with Hemoglobin data | 50 |
Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 14 |
News Archive
Leaping tall buildings in a single bound may be out of the question, but the genetically engineered "supermice" in Ormond MacDougald's laboratory at the University of Michigan Medical School are definitely stronger than average.
A new study by researchers at Wake Forest Baptist Medical Center has shown that aggressive lowering of blood pressure in people with hypertension reduced the risk of left ventricular hypertrophy (LVH).
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").
A study funded by research charity Fight for Sight aims to understand the role that our own immune cells play in the development of macular scarring.
› Verified 5 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
Adult patients getting regular hemodialysis at the center | 81 |
Adult patient months included in Kt/V greater than or equal to 1.2 | 786 |
Percentage of adult patients getting regular hemodialysis at the center | 94 |
Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Leaping tall buildings in a single bound may be out of the question, but the genetically engineered "supermice" in Ormond MacDougald's laboratory at the University of Michigan Medical School are definitely stronger than average.
A new study by researchers at Wake Forest Baptist Medical Center has shown that aggressive lowering of blood pressure in people with hypertension reduced the risk of left ventricular hypertrophy (LVH).
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").
A study funded by research charity Fight for Sight aims to understand the role that our own immune cells play in the development of macular scarring.
› Verified 5 days ago
Adult patients getting regular peritoneal dialysis at the center | 33 |
Adult patient months included in Kt/V greater than or equal to 1.7 | 298 |
Percentage of adult patients getting regular peritoneal dialysis at the center | 89 |
Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
Leaping tall buildings in a single bound may be out of the question, but the genetically engineered "supermice" in Ormond MacDougald's laboratory at the University of Michigan Medical School are definitely stronger than average.
A new study by researchers at Wake Forest Baptist Medical Center has shown that aggressive lowering of blood pressure in people with hypertension reduced the risk of left ventricular hypertrophy (LVH).
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").
A study funded by research charity Fight for Sight aims to understand the role that our own immune cells play in the development of macular scarring.
› Verified 5 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Eastchester Road Dialysis Center with elevated calcium levels.
Patients with hypercalcemia | 127 |
Hypercalcemia patient months | 1226 |
Hypercalcemia patients with serumcalcium greater than 10.2 mg | 2 |
Patients with Serumphosphor | 127 |
Patients with Serumphosphor less than 3.5 mg/dL | 5 |
Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 25 |
Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 37 |
Patients with Serumphosphor from 5.6 to 7 mg/dL | 17 |
Patients with Serumphosphor greater than 7 mg/dL | 16 |
News Archive
Leaping tall buildings in a single bound may be out of the question, but the genetically engineered "supermice" in Ormond MacDougald's laboratory at the University of Michigan Medical School are definitely stronger than average.
A new study by researchers at Wake Forest Baptist Medical Center has shown that aggressive lowering of blood pressure in people with hypertension reduced the risk of left ventricular hypertrophy (LVH).
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").
A study funded by research charity Fight for Sight aims to understand the role that our own immune cells play in the development of macular scarring.
› Verified 5 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
Patients included in arterial venous fistula and catheter summaries | 65 |
Patient months included in arterial venous fistula and catheter summaries | 544 |
Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 66 |
Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 12 |
News Archive
Leaping tall buildings in a single bound may be out of the question, but the genetically engineered "supermice" in Ormond MacDougald's laboratory at the University of Michigan Medical School are definitely stronger than average.
A new study by researchers at Wake Forest Baptist Medical Center has shown that aggressive lowering of blood pressure in people with hypertension reduced the risk of left ventricular hypertrophy (LVH).
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").
A study funded by research charity Fight for Sight aims to understand the role that our own immune cells play in the development of macular scarring.
› Verified 5 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
Patients in facility's Hospitalization Summary | 92 |
Hospitalization Rate in facility | 147.8 (As Expected) |
Hospitalization Rate: Upper Confidence Limit | 262.7 |
Hospitalization Rate: Lower Confidence Limit | 85.8 |
News Archive
Leaping tall buildings in a single bound may be out of the question, but the genetically engineered "supermice" in Ormond MacDougald's laboratory at the University of Michigan Medical School are definitely stronger than average.
A new study by researchers at Wake Forest Baptist Medical Center has shown that aggressive lowering of blood pressure in people with hypertension reduced the risk of left ventricular hypertrophy (LVH).
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").
A study funded by research charity Fight for Sight aims to understand the role that our own immune cells play in the development of macular scarring.
› Verified 5 days ago
The rate of readmission show you whether patients who were being treated regularly at Eastchester Road Dialysis Center were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
Readmission Rate in facility | 27.9 (As Expected) |
Readmission Rate: Upper Confidence Limit | 40.3 |
Readmission Rate: Lower Confidence Limit | 17.8 |
News Archive
Leaping tall buildings in a single bound may be out of the question, but the genetically engineered "supermice" in Ormond MacDougald's laboratory at the University of Michigan Medical School are definitely stronger than average.
A new study by researchers at Wake Forest Baptist Medical Center has shown that aggressive lowering of blood pressure in people with hypertension reduced the risk of left ventricular hypertrophy (LVH).
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").
A study funded by research charity Fight for Sight aims to understand the role that our own immune cells play in the development of macular scarring.
› Verified 5 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Eastchester Road Dialysis Center get infections in their blood each year compared to the number of infections expected for the center based on the national average.
Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
Infection Rate in facility | .47 (As Expected) |
SIR: Upper Confidence Limit | 1.55 |
SIR: Lower Confidence Limit | .08 |
News Archive
Leaping tall buildings in a single bound may be out of the question, but the genetically engineered "supermice" in Ormond MacDougald's laboratory at the University of Michigan Medical School are definitely stronger than average.
A new study by researchers at Wake Forest Baptist Medical Center has shown that aggressive lowering of blood pressure in people with hypertension reduced the risk of left ventricular hypertrophy (LVH).
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").
A study funded by research charity Fight for Sight aims to understand the role that our own immune cells play in the development of macular scarring.
› Verified 5 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Eastchester Road Dialysis Center's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
Patients in facility's Transfusion Summary | 84 |
Transfusion Rate in facility | 30.1 (As Expected) |
Transfusion Rate: Upper Confidence Limit | 80.2 |
Transfusion Rate: Lower Confidence Limit | 12.7 |
News Archive
Leaping tall buildings in a single bound may be out of the question, but the genetically engineered "supermice" in Ormond MacDougald's laboratory at the University of Michigan Medical School are definitely stronger than average.
A new study by researchers at Wake Forest Baptist Medical Center has shown that aggressive lowering of blood pressure in people with hypertension reduced the risk of left ventricular hypertrophy (LVH).
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").
A study funded by research charity Fight for Sight aims to understand the role that our own immune cells play in the development of macular scarring.
› Verified 5 days ago
The rate of mortality show you whether patients who were being treated regularly at Eastchester Road Dialysis Center lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
Patients in facility's Survival Summary | 483 |
Mortality Rate in facility | 15.4 (As Expected) |
Mortality Rate: Upper Confidence Limit | 21 |
Mortality Rate: Lower Confidence Limit | 10.9 |
News Archive
Leaping tall buildings in a single bound may be out of the question, but the genetically engineered "supermice" in Ormond MacDougald's laboratory at the University of Michigan Medical School are definitely stronger than average.
A new study by researchers at Wake Forest Baptist Medical Center has shown that aggressive lowering of blood pressure in people with hypertension reduced the risk of left ventricular hypertrophy (LVH).
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").
A study funded by research charity Fight for Sight aims to understand the role that our own immune cells play in the development of macular scarring.
› Verified 5 days ago
Montefiore Hosp. & Med. Ctr. Location: 111 East 210th Street, Bronx, New York, 10467 Phone: (718) 920-4974 |
ST. Barnabas Hospital Opd Dialysis Center Location: 4451 Third Avenue, Bronx, New York, 10457 Phone: (718) 960-3860 |
South Bronx Dialysis Center Location: 1940 Webster Avenue, Bronx, New York, 10457 Phone: (718) 299-9212 |
Bronx Dialysis Center Location: Knickerbocker Dialysis, Inc, Bronx, New York, 10461 Phone: (718) 892-7700 |
News Archive
Leaping tall buildings in a single bound may be out of the question, but the genetically engineered "supermice" in Ormond MacDougald's laboratory at the University of Michigan Medical School are definitely stronger than average.
A new study by researchers at Wake Forest Baptist Medical Center has shown that aggressive lowering of blood pressure in people with hypertension reduced the risk of left ventricular hypertrophy (LVH).
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").
A study funded by research charity Fight for Sight aims to understand the role that our own immune cells play in the development of macular scarring.
› Verified 5 days ago